

AMENDMENTS TO THE SPECIFICATION:

The specification is amended herein in accordance with the Examiner's remarks in the Office Action as to the use of the trademark terms being capitalized wherever they appear and be accompanied by the generic terminology:

Kindly replace the paragraph beginning on page 6, lines 19-35, and ending on page 7, lines 1-9, with the following paragraph:

2) Assay for leucotaxia or chemotaxia: A pig, bodyweight 25-30 kg, is anaesthetized with an intramuscular injection of 20 mg/kg bodyweight of KETALAR[®] (ketamine 50 mg/ml, Parke-Davis, Morris Plains, New Jersey) and an intravenous injection of 4 mg/kg bodyweight of HYPNODIL[®] (methomidate chloride 50 mg/ml, AB Leo, Helsingborg, Sweden) and 0.1 mg/kg bodyweight of STRESNIL[®] (azaperon, 2 mg/ml, Janssen Pharmaceutica, Beerse, Belgium). Anaesthesia is maintained by additional intravenous injections of 2 mg/kg bodyweight of HYPNODIL[®] and 0.05 mg/kg bodyweight of STRESNIL[®]. One ml of a fluid containing a sufficient concentration of the substance to be tested is placed, in a suitable concentration locally in its natural form, in slow-release preparations or by continuous administration by osmotic mini-pumps, in a specially designed titanium-chamber. The chamber is 5 mm high and has a diameter of 15 mm. The top could be dismantled and is perforated with 18 holes, each with a diameter of 1.4 mm. The chamber, together with one chamber with the same volume of saline, are placed subcutaneously in the lumbar region through separate incisions, with no communication between the chambers. After 7 days the pig is reanaesthetized

similar to the first procedure. The chambers are harvested and the content of the chamber is placed in a test-tube together with 1 ml of Hanks' Balanced Salt Solution (Life Technologies, Paisley, Scotland). From this suspension, 100 µl is used to wash out the chamber for remaining cells. This procedure is repeated 5 times. The test-tube is then shaken for 15 seconds. A total of 25 µl of the suspension and 25 µl of Türk's staining medium (Sigma, St Louis, USA) are mixed and placed in a chamber of Bürker. The total number of leukocytes in each chamber is determined using light microscopy. The chamber with a pro-inflammatory cytokine as defined according to the present invention then contains significantly more white blood cells than the chamber with only saline.

Kindly replace the paragraph beginning on page 10, lines 1-4, with the following paragraph:

- Phosphodiesterase I, II, III, IV, and V-inhibitors, e.g., CC-1088, Ro 20-1724, rolipram, amrinone, pimobendan, vesnarinone, SB 207499 (cilomilast) (ARIFLO®)
- Melancortin agonists, e.g., HP-228

Kindly replace the paragraph beginning on page 10, lines 29-34, with the following paragraph:

- Specific IL-1 α and IL-1 β blocking substances, such as:
 - Monoclonal antibodies
 - Soluble cytokine receptors
 - IL-1 type II receptor (decoy RII)
 - Receptor antagonists; IL-1ra, (ORTHOGEN[®], ORTHOKIN[®])
 - Antisense oligonucleotides